The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients
| Autor: | Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Comparative Effectiveness Research. 11:1337-1347 |
| ISSN: | 2042-6313 2042-6305 |
| DOI: | 10.2217/cer-2021-0232 |
| Popis: | Aim: To evaluate the safety and efficacy of insulin Aspart-Mix biosimilar candidate GP40081 (GP-Asp30) compared with NovoMix ® 30 (NN-Asp30). Materials & methods: In a randomized open-label, active-controlled, 26-week non-inferiority clinical trial 264 patients with Type 2 diabetes mellitus were randomized 1:1 to receive once-daily GP-Asp30 or NN-Asp30. The primary safety end point was the immune response rate. Efficacy outcomes were a mean change in HbA1c (primary), frequency of achieving a glycemic g fasting plasma glucose levels, 7-point glucose profiles, and insulin doses. Results: The immune response developed in 10/126 (8%) participants in the GP-Asp30 group and in 10/125 (8%) participants in the NN-Asp30 group (p = 1.000). The mean difference in HbA1c change between groups was 0.12 (95%CI [-0.14, 0.38]). Other secondary efficacy and safety outcomes weren't statistically different between the two groups. Conclusion: GP-Asp30 demonstrated similar safety and efficacy compared with NN-Asp30 and may be considered a biosimilar insulin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|